Dr. Reddy's announces the launch of Tetrabenazine Tablets in U.S. Market
02 February 2018 | News
Tetrabenazine Tablets are available in strengths of 12.5 mg and 25 mg.
Image credit- wikipedia
Dr. Reddy’s Laboratories Ltd has announced the launch of Tetrabenazine Tablets, a therapeutic equivalent generic version of Xenazine (tetrabenazine) in the United States market approved by the U.S. Food and Drug Administration (USFDA).
The Xenazine brand and generic had U.S. sales of approximately $322 million MAT for the most recent twelve months ending in November 2017 according to IMS Health.
Dr. Reddy’s Tetrabenazine Tablets are available in strengths of 12.5 mg and 25 mg, each strength is available in a bottle count size of 112.
Xenazine is a registered trademark of Valeant Pharmaceuticals Luxembourg S.A.R.L.
